Core Viewpoint - Picard Medical, Inc. has announced the pricing of its initial public offering (IPO), aiming to raise $17 million through the sale of 4,250,000 shares at $4.00 per share, with trading expected to commence on August 29, 2025 under the ticker symbol "PMI" [1][3]. Group 1: Offering Details - The IPO consists of 4,250,000 shares priced at $4.00 each, totaling gross proceeds of $17 million before expenses [1]. - Underwriters have an option to purchase an additional 637,500 shares within 30 days to cover over-allotments [1]. - The offering is being conducted on a firm commitment basis, with WestPark Capital, Inc. as the Lead Manager and Sole Bookrunner [2]. Group 2: Use of Proceeds - Proceeds from the IPO will support market expansion in China through a joint venture, fund research and development for new products, and enhance sales and marketing capabilities [3]. - The funds will also be used to repay debt and cover general operational expenses and working capital [3]. Group 3: Company Background - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which manufactures the SynCardia Total Artificial Heart (STAH), the only FDA and Health Canada approved total artificial heart [6]. - The STAH is the most widely used artificial heart globally, with over 2,100 implants performed in 27 countries [6].